2-hydroxypropylvaline: RN given refers to (DL)-isomer; RN for cpd without isomeric designation not available 11/88 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 130204 |
| SCHEMBL ID | 3566341 |
| MeSH ID | M0160743 |
| Synonym |
|---|
| 2-hydroxypropylvaline |
| 91147-54-5 |
| n-(2-hydroxypropyl)-l-valine |
| 101834-32-6 |
| l-valine, n-(2-hydroxypropyl)- |
| dl-valine, n-(2-hydroxypropyl)- |
| n-(2-hydroxypropyl)valine |
| LQFKABMWUHITQU-MLWJPKLSSA-N |
| SCHEMBL3566341 |
| DTXSID20906737 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response for accumulation of DNA adducts was similar to that obtained for Hb adducts." | ( Exposure-dependent accumulation of N-(2-hydroxypropyl)valine in hemoglobin of F344 rats exposed to propylene oxide by the inhalation route. Filser, JG; Lee, MS; Ranasinghe, A; Ríos-Blanco, MN; Swenberg, JA; Upton, P, 2002) | 0.31 |
| " Within the range of concentrations where the dose-response curves for adduct formation are linear, the relationship between exposure dose and resulting tissue doses could be based equally well on adduct data from the short-term exposure as on adduct data from the prolonged exposure." | ( Dosimetry by means of DNA and hemoglobin adducts in propylene oxide-exposed rats. Csanády, GA; Czene, K; Faller, TH; Filser, JG; Kessler, W; Lee, MS; Osterman-Golkar, S; Pérez, HL; Segerbäck, D, 2003) | 0.32 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||